1 / 27

Vascular issues associated with bevacizumab

Vascular issues associated with bevacizumab. Stuart M. Lichtman, MD, FACP 65+ Clinical Geriatric Program Associate Attending Memorial Sloan-Kettering Cancer Center New York. Bevacizumab. Improved survival in first line metastatic colorectal cancer with chemotherapy

drew-turner
Download Presentation

Vascular issues associated with bevacizumab

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Vascular issues associated with bevacizumab Stuart M. Lichtman, MD, FACP 65+ Clinical Geriatric Program Associate Attending Memorial Sloan-Kettering Cancer Center New York

  2. Bevacizumab • Improved survival in first line metastatic colorectal cancer with chemotherapy • Improved survival in previously treated metastatic colorectal cancer • Improved survival in previously untreated nonsquamous nonsmall cell lung cancer • Improved PFS in previously untreated metastatic breast cancer

  3. Bevacizumab • In pivotal trial of metastatic colorectal cancer 3.3% vs. 1.0% (placebo) experienced arterial thrombotic event • No increased incidence of venous thromboembolism Scappaticci 2007

  4. ATE • angina pectoris, arterial thrombosis, cerebral infarct, cerebral ischemia, cerebrovascular accident, myocardial infarction, and myocardial ischemia.

  5. Exclusions Within 1 year of study entry • un -controlled hypertension • myocardial infarction • unstable angina • congestive heart failure NYHA class II or higher • serious cardiac arrhythmia requiring medication • grade 2 or higher peripheral vascular disease any history of • stroke • chronic daily treatment with aspirin (>325 mg/day) • nonsteroidal anti-inflammatory medications at doses known to inhibit platelet function • Current full-dose anticoagulation (within 10 days before treatment)

  6. ATE Scappaticci 2007

  7. Patients • 1745 patients • Colorectal cancer 69% • Breast cancer 25% • Non small cell lung 6% • Fluoropyrimidine based therapy 94% • Bevacizumab • 5 mg/kg/week 31% • 2.5 mg/kg/week 69% Scappaticci 2007

  8. ATE Overall Difference in ATE 3.8% vs. 1.7% Rate per 100 person years 5.5 vs. 3.1 ATE causing death 0.62% vs. 0.26% VTE 9.97% vs. 9.85% Scappaticci 2007

  9. Time to First ATE Scappaticci 2007

  10. Risk Factors • Evaluated: • Exposure to bevacizumab • Age >65 years • Hypertension at baseline • History of ATE • History of atherosclerosis • History of myocardial infarction Scappaticci 2007

  11. Risk Factors • Evaluated: • Exposure to bevacizumab (P=0.04) • Age >65 years (P=0.01) • Hypertension at baseline • History of ATE (P<0.001) • History of atherosclerosis • History of myocardial infarction Scappaticci 2007

  12. Risk Factors Scappaticci 2007

  13. Elderly Patients and the Risk ofArterial Thromboembolic Events (ATEs) Scappaticci 2007

  14. Elderly Patients and the Risk ofArterial Thromboembolic Events (ATEs) Scappaticci 2007

  15. ATE Incidence by Risk Group Scappaticci 2007 *not mutually exclusive

  16. ATE Incidence by Risk Group Scappaticci 2007 *not mutually exclusive

  17. ATE Incidence by Risk Group Scappaticci 2007 *not mutually exclusive

  18. ATE Incidence by Risk Group Scappaticci 2007 *not mutually exclusive

  19. Aspirin Use • More common patients with history of ATE • Aspirin use associated with increased risk of bleeding in both groups • No difference between bevacizumab and control • Data not adequate to comment on prophylaxis Scappaticci 2007

  20. Risk-Benefit Scappaticci 2007

  21. Lung CancerPaclitaxel/Carboplatin +/- bevacizumab Ramalingam 2008

  22. Lung CancerPaclitaxel/Carboplatin +/- bevacizumab • Elderly patients had higher incidence of grade 3 to 5 neutropenia, bleeding, and proteinuria with PCB compared with younger patients. Conclusion In elderly NSCLC patients, PCB was associated with a higher degree of toxicity, but no obvious improvement in survival compared with PC. Data from this unplanned, retrospective analysis justify prospective evaluation of the therapeutic index of PCB regimen in elderly patients. Ramalingam 2008

  23. BevacizumabLong Term: BRITEObservational Cohort Median followup 20.8 months ASCO 2008

  24. Safety and effectiveness of bevacizumab (BV) and chemotherapy (CT) in elderly patients (pts) with metastatic colorectal cancer (mCRC): Results from the BRiTE Prospective Cohort Study GI ASCO 2008

  25. Initial safety report of NSABP C-08, a randomized phase III study of modified 5-fluorouracil /leucovorin and oxaliplatin (mFOLFOX6) with or without bevacizumab in the adjuvant treatment of patients with stage II/III colon cancer. ASCO 2008

  26. Questions • Is this risk applicable to general elderly population? • What should be recommended to patients with increased comorbidity? • What should be recommended to patients with more recent ATE? • Were there functional consequences of ATE which affect QOL?/

  27. Conclusion • Bevacizumab is an important component of therapy in various solid tumors • Vascular complications of therapy is a well recognized entity • Patient selection is critical to ensure safety with this palliative treatment

More Related